Company / R&D Expense
Kymera Therapeutics, Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$316.6M
FY2025
5-year range
$37.2M / $316.6M
FY2021-FY2025
Trend
+31.8%
vs FY2024
Sector context
#57 of 210
Health Care
What the data says
At $317M, Kymera Therapeutics, Inc.'s r&d expense ranks #57 of 210 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $37M in FY2021 to $317M in FY2025.
Based on SEC 10-K filings.
$317M in FY2025 with a 5-year CAGR of +53.5%.
Improved from $189M to $317M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +24.4%
- 5-Year CAGR
- +53.5%
- 10-Year CAGR
- -
Sector benchmark
#57 of 210 in Health CareTop 27% of 210This company $316.6M Sector average $644.0M
▼
-50.8% below sector average
Key checks
Key Insights
- Kymera Therapeutics, Inc.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +53.5%, indicating consistent growth.
- In FY2025, r&d expense increased 31.8% year-over-year.
- Ranks #57 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $316.6M | +31.8% |
| FY2024 | $240.2M | +27.1% |
| FY2023 | $189.1M | +15.1% |
| FY2022 | $164.2M | +342.0% |
| FY2021 | $37.2M | +0.0% |
| FY2020 | $37.2M | +0.0% |
| FY2019 | $37.2M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026